Pei regimen: A therapeutic option in small cell lung cancer? A retrospective monoinstitutional analysis of 46 consecutive cases

3Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Objectives: Combination chemotherapy is very active in small cell lung cancer (SCLC), although no improvement in overall survival (OS) has been done in the last 25 years, with Cisplatin-Etoposide (PE) still considered the world-wide standard, with an average median survival of about 7-8 months in patients with extended disease (ED). Materials and methods: Here we present a retrospective analysis of 46 consecutive patients (30 males and 16 females) with SCLC that were treated at our Institution with PEI regimen: Cisplatin 20 mg/m2, Etoposide 75 mg/m2 and Ifosfamide 1200 mg/m2, day 1 to 4, every 3 weeks. Results: In 19 limited disease (LD) patients partial response (PR) rate was 74%, and complete response (CR) was 16%. In 27 ED patients we observed 63% of PR and 26% of CR. Conclusions: PEI regimen, in our opinion, may be a possible therapeutic option, with high activity and an acceptable toxicity profile.

Cite

CITATION STYLE

APA

Boni, C., Pagano, M., Baldi, L., Gnoni, R., Braglia, L., Savoldi, L., & Zanelli, F. (2015). Pei regimen: A therapeutic option in small cell lung cancer? A retrospective monoinstitutional analysis of 46 consecutive cases. Journal of Translational Medicine, 13(1). https://doi.org/10.1186/s12967-015-0491-3

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free